Open AccessTolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia
Author(s) -
Robert W. Schrier,
Peter Groß,
Mihai Gheorghiade,
Tomás Berl,
Joseph G. Verbalis,
Frank S. Czerwiec,
Cesare Orlandi
Publication year - 2006
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa065181
Subject(s) - tolvaptan , hyponatremia , medicine , vasopressin , antagonist , vasopressin antagonists , cirrhosis , endocrinology , heart failure , receptor antagonist , arginine vasopressin receptor 2 , electrolyte disorder , vasopressin receptor , pharmacology , receptor
Hyponatremia (serum sodium concentration, <135 mmol per liter) is a predictor of death among patients with chronic heart failure and cirrhosis. At present, therapy for acute and chronic hyponatremia is often ineffective and poorly tolerated. We investigated whether tolvaptan, an orally active vasopressin V(2)-receptor antagonist that promotes aquaresis--excretion of electrolyte-free water--might be of benefit in hyponatremia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom